Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth - Yakes, F M; Chen, J; Tan, J (Mol Cancer Ther, 2011)
, et al.